Miraca Holdings Incorporated operates in the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Miraca Holdings Incorporated with three other
pharmaceutical manufacturers in Asia:
Dr. Lal PathLabs Ltd
sales of 12.03 billion Indian Rupees [US$168.48 million]
of which 100%
was Laboratories for pathological investigat),
(117.13 billion Japanese Yen [US$1.10 billion]
of which 95%
was Examination business), and
Falco Holdings Co Ltd
(44.16 billion Japanese Yen [US$414.18 million]
Miraca Holdings Incorporated reported sales of ¥181.42 billion (US$1.70 billion)
March of 2019.
decrease of 7.2%
versus 2018, when the company's sales were ¥195.40 billion.
Contributing to the drop in overall sales was the 11.4% decline
in Clinical Examination, from ¥121.96 billion to ¥108.08 billion.
There were also decreases in sales in
Healthcare (down 0.7% to ¥27.93 billion)
However, these declines were partially offset by the increase in sales of
Clinical Medical Check (up 0.2% to ¥45.40 billion)